Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 16.14 -9.12% -1.62
FATE closed down 9.12 percent on Friday, March 22, 2019, on 1.16 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical FATE trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -9.12%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -9.12%
Mar 20 1,2,3 Pullback Bullish Bullish Swing Setup -8.56%
Mar 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -8.56%
Mar 20 Down 3 Days in a Row Weakness -8.56%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup -10.38%

Older signals for FATE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Biology Stem Cells Hematologic Malignancies Orphan Diseases Cord Blood Induced Stem Cells Adult Stem Cell Lysosomal Storage Disorders
Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.11
52 Week Low 8.35
Average Volume 659,464
200-Day Moving Average 13.5847
50-Day Moving Average 15.7244
20-Day Moving Average 16.853
10-Day Moving Average 17.618
Average True Range 1.0197
ADX 35.1
+DI 23.0265
-DI 17.4697
Chandelier Exit (Long, 3 ATRs ) 16.0509
Chandelier Exit (Short, 3 ATRs ) 16.9091
Upper Bollinger Band 18.7697
Lower Bollinger Band 14.9363
Percent B (%b) 0.31
BandWidth 22.746099
MACD Line 0.6345
MACD Signal Line 0.6873
MACD Histogram -0.0528
Fundamentals Value
Market Cap 668.42 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -16.81
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.56
Resistance 3 (R3) 18.82 18.28 18.15
Resistance 2 (R2) 18.28 17.66 18.15 18.02
Resistance 1 (R1) 17.21 17.29 16.94 16.95 17.88
Pivot Point 16.67 16.67 16.54 16.54 16.67
Support 1 (S1) 15.60 16.05 15.33 15.34 14.40
Support 2 (S2) 15.06 15.68 14.93 14.26
Support 3 (S3) 13.99 15.06 14.13
Support 4 (S4) 13.73